- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Single use pre-filled syringe containing brolucizumab.
Treatment of neovascular age-related macular degeneration
Treatment of visual impairment due to diabetic macular oedema
Neovascular (wet) age-related macular degeneration (AMD)
6mg once every 4 weeks, for 12 weeks.
No disease activity after 16 weeks
6mg every 12 weeks.
Disease activity after 16 weeks
6mg every 8 weeks.
Visual impairment due to diabetic macular oedema (DME)
6mg once every 6 weeks, for the first 5 doses.
No disease activity after 5 doses
6mg every 12 weeks.
Disease activity after 5 doses
6mg every 8 weeks.
For intravitreal injection only.
The intravitreal injection should be carried out under aseptic conditions.
The interval between doses during maintenance treatment should not be less than 8 weeks to reduce the risk of intraocular inflammation including retinal vasculitis and retinal vascular occlusion, which has a higher incidence with shorter dosing intervals.
Children under 18 years
Recent ocular surgery
Precautions and Warnings
Females of childbearing potential
Risk factors for retinal pigment epithelial tears
History of cerebrovascular accident
History of transient ischaemic attack
Within 3 months of a myocardial infarction
Suspend treatment if planned surgery within next 28 days
Advise visual disturbances may affect ability to drive or operate machinery
Aseptic technique should be used throughout
Do not start therapy for 28 days post surgery, or until wound has healed
Protect anaesthetised eye from dust and bacterial contamination
Record name and batch number of administered product
Treatment to be administered by or under supervision of specialist
Vary injection site during prolonged therapy
Monitor intra-ocular pressure post injection and manage appropriately
Monitor visual acuity during and after treatment
Advise patient to report any symptoms of endophthalmitis immediately
Advise patient to report any symptoms of retinal detachment immediately
Advise patient to report any unexpected changes in eye symptoms immediately
Discontinue if intraocular inflammation or retinal vascular occlusion occur
Discontinue if rhegmatogenous retinal detachment or stage 3/4 macular holes
Suspend if best-corrected visual activity declines by 30 letters or more
Suspend treatment if central foveal haemorrhage
Suspend treatment if foveal haemorrhage >50% of the total lesion area
Suspend treatment if intraocular pressure of >29 mmHg
Suspend treatment if retinal break or tear develops
Female: May cause infertility
Female: Contraception required during and for 1 month after treatment
Breastfeeding: Do not breastfeed during & for 1 month after treatment
Brolucizumab should not be administered concurrently with other anti-VEGF medicinal products (systemic or ocular).
A higher number of intraocular inflammation events were observed among patients with treatment-emergent antibodies. After investigation, retinal vasculitis and/or retinal vascular occlusion were found to be immune-mediated events. Intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion, may occur following the first intravitreal injection and at any time of treatment. These events were observed more frequently at the beginning of treatment.
Pregnancy and Lactation
Use brolucizumab with caution during pregnancy.
The manufacturer recommends brolucizumab is not used during pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. There are no or limited amount of data from the use of brolucizumab in pregnant women. Animal studies are insufficient to determine reproductive toxicity. After ocular use, systemic exposure to brolucizumab is low, but there is a potential risk to embryofoetal development. Brolucizumab should not be used during pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus.
Brolucizumab is contraindicated during breastfeeding.
The manufacturer advises that brolucizumab is not recommended when breastfeeding and for at least 1 month after the final dose. It is not known whether brolucizumab is excreted in human milk, therefore a risk to the infant cannot be excluded.
Abnormal sensation in eye
Anterior chamber flare
Anterior chamber inflammation
Detachment of the retinal pigment epithelium
Increased intra-ocular pressure
Reduced visual acuity
Retinal artery occlusion
Retinal pigment epithelial tear
Retinal vascular occlusion
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: December 2021
Summary of Product Characteristics: Beovu 120 mg/ml solution for injection in pre-filled syringe. Novartis Pharmaceuticals UK Ltd. Revised April 2022.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 08 December 2022
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.